BD DIFCO PURPLE BROTH BASE
Report
- Report Number
- 1119779-2021-00882
- Event Type
- Malfunction
- Date Received
- May 25, 2021
- Date of Event
- April 27, 2021
- Report Date
- June 3, 2021
- Manufacturer
- BECTON, DICKINSON & CO. (SPARKS)
- Product Code
- JSG
- PMA / PMN Number
- EXEMPT
- Product Problem
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- CA
- Reporter Occupation
- OTHER HEALTH CARE PROFESSIONAL
Narratives
H6: INVESTIGATION SUMMARY: THE COMPLAINT INVESTIGATION INCLUDED A REVIEW OF THE BATCH HISTORY RECORD. THE BATCH HISTORY RECORD REVIEW INDICATED NO DISCREPANCIES. ALL RELEASE TESTING WAS SATISFACTORY. RELEASE TESTING CONSISTS OF DEHYDRATED MEDIUM APPEARANCE, SOLUBILITY, SOLUTION APPEARANCE, PH AND CULTURAL RESPONSE WITH ORGANISMS SPECIFIED ON THE BD CERTIFICATE OF ANALYSIS. THE COMPLAINT TRENDS WERE REVIEWED FOR A PERIOD COVERING 12 MONTHS. DURING THAT TIME, THERE HAVE BEEN NO CONFIRMED COMPLAINTS ON THIS PRODUCT FOR THE DEFECT IN QUESTION. NO RETURNS WERE RECEIVED. THE COMPLAINT STATES THAT PURPLE BROTH BASE IS USED IN CONJUNCTION WITH AGAR AND RHAMNOSE OR XYLOSE AND OBTAINING UNDESIRED POSITIVE REACTIONS WITH LISTERIA GRAYI. LISTERIA GRAYI IS NOT TESTED FOR RELEASE OF THIS PRODUCT; CONSEQUENTLY, BD DOES NOT HAVE ACCESS TO THIS ORGANISM AND IS UNABLE TO DUPLICATE THE CUSTOMER¿S APPLICATION. IN ADDITION, BD DOES NOT HAVE ANY HISTORICAL DATA RELATED TO THE PERFORMANCE OF LISTERIA IN PURPLE BROTH BASE. THIS COMPLAINT CANNOT BE CONFIRMED.
A DEVICE EVALUATION AND/OR DEVICE HISTORY REVIEW IS ANTICIPATED, BUT IS NOT COMPLETE. UPON COMPLETION, A SUPPLEMENTAL REPORT WILL BE FILED.
IT WAS REPORTED THAT WHILE USING 2 BD DIFCO¿ PURPLE BROTH BASE ATYPICAL GROWTH WAS OBSERVED BY THE LABORATORY PERSONNEL. THERE WAS NO INDICATION THAT RESULTS WERE REPORTED OUT AND THERE WAS NO REPORT OF PATIENT IMPACT. THE FOLLOWING INFORMATION WAS PROVIDED BY THE INITIAL REPORTER: " IT WAS REPORTED THAT UNDESIRED POSITIVE REACTION WHEN STREAKING LISTERIA GRAYI. CUSTOMER PROBLEM: CUSTOMER REPORTED USING THIS PRODUCT 222710 (2 EA) LOT 9231550 (PO# (B)(4)) TO MAKE XYLOSE AND RHAMNOSE AGARS, THE AGARS ARE PRODUCING AN UNDESIRED POSITIVE REACTION WHEN STREAKING LISTERIA GRAYI. THIS PROBLEM IS ONLY OCCURRING WITH THE AFOREMENTIONED COMBINATION AND THE INVESTIGATION CONDUCTED IN OUR LAB LED US TO TRY MAKING THE PURPLE BROTH BASE FROM ITS INDIVIDUAL COMPONENTS WHICH SOLVED THE ISSUE. WE CURRENTLY HAVE TWO BOTTLES OF THE SAME LOT, BOTH OF WHICH PRODUCED THE SAME UNDESIRED RESULT WITH L.GRAYI ON RHAMNOSE AND XYLOSE. ALL OTHER CARBOHYDRATE SOLUTIONS USED IN CONJUNCTION WITH THE ABOVE LOT OF PURPLE BROTH BASE PRODUCED SATISFACTORY RESULTS WHEN STREAKING THEIR RESPECTIVE ORGANISMS."
IT WAS REPORTED THAT WHILE USING 2 BD DIFCO¿ PURPLE BROTH BASE ATYPICAL GROWTH WAS OBSERVED BY THE LABORATORY PERSONNEL. THERE WAS NO INDICATION THAT RESULTS WERE REPORTED OUT AND THERE WAS NO REPORT OF PATIENT IMPACT. THE FOLLOWING INFORMATION WAS PROVIDED BY THE INITIAL REPORTER: " IT WAS REPORTED THAT UNDESIRED POSITIVE REACTION WHEN STREAKING LISTERIA GRAYI. ¿ CUSTOMER PROBLEM: CUSTOMER REPORTED USING THIS PRODUCT 222710 (2 EA) LOT 9231550 (PO# (B)(4)) TO MAKE XYLOSE AND RHAMNOSE AGARS, THE AGARS ARE PRODUCING AN UNDESIRED POSITIVE REACTION WHEN STREAKING LISTERIA GRAYI. THIS PROBLEM IS ONLY OCCURRING WITH THE AFOREMENTIONED COMBINATION AND THE INVESTIGATION CONDUCTED IN OUR LAB LED US TO TRY MAKING THE PURPLE BROTH BASE FROM ITS INDIVIDUAL COMPONENTS WHICH SOLVED THE ISSUE. WE CURRENTLY HAVE TWO BOTTLES OF THE SAME LOT, BOTH OF WHICH PRODUCED THE SAME UNDESIRED RESULT WITH L.GRAYI ON RHAMNOSE AND XYLOSE. ALL OTHER CARBOHYDRATE SOLUTIONS USED IN CONJUNCTION WITH THE ABOVE LOT OF PURPLE BROTH BASE PRODUCED SATISFACTORY RESULTS WHEN STREAKING THEIR RESPECTIVE ORGANISMS. "
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 775618 | BD DIFCO PURPLE BROTH BASE | CULTURE MEDIA, NON-SELECTIVE AND NON-DIFFERENTIAL | JSG | BECTON, DICKINSON & CO. (SPARKS) | 9231550 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 |